Drugs / TP53-R248Q mutant TCR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06619886 | Sep 2024 → Oct 2026 expected | colorectal cancer, lung adenocarcinoma, malignant pancreatic neoplasm | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP53-R248Q mutant TCR-T Cells | “TP53-R248Q mutant TCR-T Cells Injection, 28 days as a treatment cycle” NCT06619886 ↗ |
| Action | Deplete | “we have successfully developed a TCR-T cell specific killing function for tumor cells targeting the R248Q mutation” NCT06619886 ↗ |
| Modality | Cell therapy | “TCR-T cell therapy” NCT06619886 ↗ |
| Target | TP53 | “targeting the R248Q mutation of the most common TP53 protein” NCT06619886 ↗ |